Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GIST has been shown to over-express c-KIT (CD117), the receptor tyrosine kinase. Imatinib (STI571 or Glivec) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases and has been successfully used to trea...

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumors of the gastrointestinal tract. In this report, we present a case of GIST patient who had been treated with imatinib, but developed leiomyoma and intra-abdominal fibromatosis (IAF) at the site of GIST resection beds mimicking recurrent GIST. To our knowledge, no patient with the 3 gastrointestinal tumor types we encounte...

Gastrointestinal stromal tumors (GIST) most commonly arise from the stomach followed by the small intestine and are common cause for an occult gastrointestinal (GI) bleeding. We present an unusual case of a jejunal GIST, which presented as an acute gastrointestinal haemorrhage. This case highlights the importance of an intravenous contrast enhanced abdominal CT with neutral oral contrast for th...

Stromal tumors represent 1-3% of all primary gastric neo-plasms. These tumors can occur at any age and display different clinical manifestations, but they rarely reach over 10 cm in size. Currently they are designed as gastrointestinal stromal tumors (GIST) but their classification is still controversial. Surgery is the treatment of choice, and the extension of surgical resection depends on the...

BACKGROUND Gastrointestinal stromal (GIST) tumors make <1% of all gastrointestinal neoplasms and 20% of small bowel neoplasms. The most common acute presenting symptom of these tumors is gastrointestinal hemorrhage with obstruction being rare. We discuss our laparoscopic approach to 2 patients with small bowel GIST tumors that presented to our institution with obstruction of the small bowel. ...

1. Arezzo A, Verra M, Morino M. Transanal endoscopic microsurgery after neoadjuvant therapy for rectal GIST. Digestive and Liver Disease 43 (2011) 921– 924. 2. Blay JY, Bonvalot S, Casali P, et al. GIST consensus meeting panellists: Consensus meeting for the management of gastrointestinal stromal tumours. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. A...

INTRODUCTION Gastrointestinal stromal tumors are the commonest mesenchymal tumors of the gastrointestinal tract, the stomach and small intestine are the favored sites of occurrence. They rarely occur in the colon, rectum and esophagus. GIST is neoplasm of mesenchymal origin originating from precursors of the interstitial cells of cajal. The symptoms of gastrointestinal stromal tumor depend on t...

Gastrointestinal stromal tumors (GIST) have a variety of appearances and can present as an intraluminal, extraluminal, solid or ulcerated mass. We present an unusual case of a patient presenting with pain, elevated white count, and computed topography (CT) findings suggesting an abscess containing bone. CT guided drainage was performed, and resulted in bowel perforation, leading to surgical int...

Abstract Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to imatinib, with the notable exception most common mutation, D842V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor substantial clinical activity in patients D842V genotype. To date, only minority PDGFRA-mutant treated avapritinib have developed secondary resistance. Tumor and plasma biopsies 6...

Gastrointestinal stromal tumor (GIST) is a relatively rare type of cancer that affects an estimated 5000 to 10,000 new people each year in the US. Most GIST tumors develop in the stomach; but they can also arise in the small intestine, colon and rectum, esophagus or abdominal cavity. Gastrointestinal stromal tumors are the most common mesenchymal, nonepithelial tumors of the gastrointestinal tr...